Peroxisome proliferator-activated receptor α agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 2, 2010, Pages 324-331

  Gelosa, Paolo ^a   Banfi, Cristina ^b   Gianella, Anita ^b   Brioschi, Maura ^b   Pignieri, Alice ^a   Nobili, Elena ^b   Castiglioni, Laura ^a   Cimino, Mauro ^c   Tremoli, Elena ^a,b   Sironi, Luigi ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b CENTRO CARDIOLOGICO MONZINO   (Italy)

^c UNIVERSITY OF URBINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ADVANCED OXIDATION PROTEIN PRODUCT; CLOFIBRATE; COLLAGEN; FENOFIBRATE; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; ROSIGLITAZONE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; ENCEPHALITIS; GENE EXPRESSION; GLOMERULOSCLEROSIS; KIDNEY INJURY; KIDNEY TUBULE DAMAGE; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CARBONYLATION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RENAL PROTECTION; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; SURVIVAL;

ANIMALS; BLOTTING, WESTERN; BRAIN; CHEMOKINE CCL2; CLOFIBRATE; DISEASE MODELS, ANIMAL; FENOFIBRATE; HYPERTENSION; INFLAMMATION; INTERLEUKIN-1BETA; KIDNEY DISEASES; LIGANDS; MALE; OXIDATIVE STRESS; PPAR ALPHA; RATS; RATS, INBRED SHR; STROKE; TRANSFORMING GROWTH FACTOR BETA;

EID: 78149277100     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.171090     Document Type: Article

References (40)

1. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G, and DAIS Investigators (2005) Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45:485-493.
2. Banfi C, Auwerx J, Poma F, Tremoli E, and Mussoni L (2003) Induction of plasminogen activator inhibitor I by the PPARα ligand, Wy-14,643, is dependent on ERK1/2 signaling pathway. Thromb Haemost 90:611-619.
3. Banfi C, Brioschi M, Barcella S, Veglia F, Biglioli P, Tremoli E, and Agostoni P (2008) Oxidized proteins in plasma of patients with heart failure: role in endothelial damage. Eur J Heart Fail 10:244-251.
4. Besson VC, Chen XR, Plotkine M, and Marchand-Verrecchia C (2005) Fenofibrate, a peroxisome proliferator-activated receptor α agonist, exerts neuroprotective effects in traumatic brain injury. Neurosci Lett 388:7-12.
5. Blezer EL, Nicolay K, Bär D, Goldschmeding R, Jansen GH, Koomans HA, and Joles JA (1998) Enalapril prevents imminent and reduces manifest cerebral edema in stroke-prone hypertensive rats. Stroke 29:1671-1677; discussion 1677-1678.
6. Bordet R, Ouk T, Petrault O, Gelé P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, et al. (2006) PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 34:1341-1346.
7. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
8. Butterfield DA, Hensley K, Cole P, Subramaniam R, Aksenov M, Aksenova M, Bummer PM, Haley BE, and Carney JM (1997) Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer's disease. J Neurochem 68:2451-2457.
9. Collino M, Aragno M, Mastrocola R, Benetti E, Gallicchio M, Dianzani C, Danni O, Thiemermann C, and Fantozzi R (2006) Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-α agonist WY14643. Free Radic Biol Med 41:579-589.
10. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, and Milzani A (2003) Protein carbonylation in human diseases. Trends Mol Med 9:169-176.
11. Delerive P, Fruchart JC, and Staels B (2001) Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169:453-459.
12. Deplanque D, Gelé P, Pétrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, et al. (2003) Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 23:6264-6271.
13. Gelosa P, Pignieri A, Fändriks L, de Gasparo M, Hallberg A, Banfi C, Castiglioni L, Turolo L, Guerrini U, Tremoli E, et al. (2009) Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens 27: 2444-2451.
14. Gianella A, Nobili E, Abbate M, Zoja C, Gelosa P, Mussoni L, Bellosta S, Canavesi M, Rottoli D, Guerrini U, et al. (2007) Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Am J Pathol 170:1165-1177.
15. Griffiths HR (2000) Antioxidants and protein oxidation. Free Radic Res 33 (Suppl): S47-S58.
16. Guerrini U, Sironi L, Tremoli E, Cimino M, Pollo B, Calvio AM, Paoletti R, and Asdente M (2002) New insights into brain damage in stroke-prone rats: a nuclear magnetic imaging study. Stroke 33:825-830.
17. Hyong A, Jadhav V, Lee S, Tong W, Rowe J, Zhang JH, and Tang J (2008) Rosiglitazone, a PPAR γ agonist, attenuates inflammation after surgical brain injury in rodents. Brain Res 1215:218-224.
18. Inoue H, Jiang XF, Katayama T, Osada S, Umesono K, and Namura S (2003) Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor α in mice. Neurosci Lett 352:203-206.
19. Ito S, Nagasawa T, Abe M, and Mori T (2009) Strain vessel hypothesis: a viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. Hypertens Res 32:115-121.
20. Jiang G, Dallas-Yang Q, Biswas S, Li Z, and Zhang BB (2004) Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor γ (PPARγ), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo. Biochem J 377:339-346.
21. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, et al. (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849-1861.
22. Khella S and Bleicher MB (2007) Stroke and its prevention in chronic kidney disease. Clin J Am Soc Nephrol 2:1343-1351.
23. Kockx M, Gervois PP, Poulain P, Derudas B, Peters JM, Gonzalez FJ, Princen HM, Kooistra T, and Staels B (1999) Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-α. Blood 93:2991-2998.
24. Lakhan SE, Kirchgessner A, and Hofer M (2009) Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med 17:7-97.
25. Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B, Kalina Z, and Herman ZS (1998) Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther 36:345-349.
26. Marx N, Sukhova GK, Collins T, Libby P, and Plutzky J (1999) PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99:3125-3131.
27. Morgan EE, Rennison JH, Young ME, McElfresh TA, Kung TA, Tserng KY, Hoit BD, Stanley WC, and Chandler MP (2006) Effects of chronic activation of peroxisome proliferator-activated receptor-α or high-fat feeding in a rat infarct model of heart failure. Am J Physiol Heart Circ Physiol 290:H1899-H1904.
28. Ouk T, Pétrault O, Gautier S, Gelé P, Laprais M, Duriez P, Bastide M., and Bordet R (2005) Acute treatment by a PPAR-α agonist decreases cerebral infarct volume and prevents post-ischemic endothelium and Kir 2.1 impairment. J Cereb Blood Flow Metab 25:S56.
29. Pantke U, Volk T, Schmutzler M, Kox WJ, Sitte N, and Grune T (1999) Oxidized proteins as a marker of oxidative stress during coronary heart surgery. Free Radic Biol Med 27:1080-1086.
30. Park HY, Schumock GT, Pickard AS, and Akhras K (2003) A structured review of the relationship between microalbuminuria and cardiovascular events in patients with diabetes mellitus and hypertension. Pharmacotherapy 23:1611-1616.
31. Poynter ME and Daynes RA (1998) Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273:32833-32841.
32. Siems WG, Zollner H, Grune T, and Esterbauer H (1997) Metabolic fate of 4-hydroxynonenal in hepatocytes: 1,4-dihydroxynonene is not the main product. J Lipid Res 38:612-622.
33. Sironi L, Gelosa P, Guerrini U, Banfi C, Crippa V, Brioschi M, Gianazza E, Nobili E, Gianella A, de Gasparo M, et al. (2004) Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. J Pharmacol Exp Ther 311:989-995.
34. Sironi L, Gianazza E, Gelosa P, Guerrini U, Nobili E, Gianella A, Cremonesi B, Paoletti R, and Tremoli E (2005) Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects. Arterioscler Thromb Vasc Biol 25:598-603.
35. Sironi L, Tremoli E, Miller I, Guerrini U, Calvio AM, Eberini I, Gemeiner M, Asdente M, Paoletti R, and Gianazza E (2001) Acute-phase proteins before cerebral ischemia in stroke-prone rats: identification by proteomics. Stroke 32:753-760.
36. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, et al. (1998) Activation of human aortic smoothmuscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393:790-793.
37. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, and Landreth GE (2005) Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130:685-696.
38. Townsend RR (2008) Stroke in chronic kidney disease: prevention and management. Clin J Am Soc Nephrol 3 (Suppl 1):S11-S16.
39. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, and Descamps-Latscha B (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49:1304-1313.
40. Zhao X, Strong R, Zhang J, Sun G, Tsien JZ, Cui Z, Grotta JC, and Aronowski J (2009) Neuronal PPARγ deficiency increases susceptibility to brain damage after cerebral ischemia. J Neurosci 29:6186-6195.